Do GLP-1 medications cause vision loss? What the studies show

Recent headlines put a frightening word next to your weight-loss medication: blindness. Two large 2026 studies found that people taking GLP-1 medications like Ozempic and Wegovy had a slightly higher rate of a rare optic-nerve condition than people on other diabetes drugs. Before you panic or stop your treatment, here is what those numbers actually mean.

TL;DR

Two studies published in Annals of Internal Medicine in 2026 link GLP-1 medications to a small increase in ischemic optic neuropathy, a rare condition that can cause sudden, often permanent vision loss in one eye. The absolute risk is very low, roughly one extra case for every 2,500 to 3,300 people treated over 1.5 to 3 years, and eye specialists say the benefits of these drugs still outweigh this risk for most patients.

What the two new studies actually found

For most of 2024 and 2025, the link between semaglutide and eye damage rested on a single much-discussed report. In July 2024, researchers at Harvard's Massachusetts Eye and Ear found that patients prescribed semaglutide appeared to have a higher risk of nonarteritic anterior ischemic optic neuropathy, usually shortened to NAION. That study was relatively small and raised more questions than it answered. The two 2026 studies are far larger, and together they give the clearest picture yet.

The US study: about 3 extra cases per 10,000 people

Kamika Reynolds and colleagues at the Rutgers Institute for Health ran what researchers call a target trial emulation, using US insurance claims from 2017 to 2022. They compared 161,489 people who started a GLP-1 medication against 122,114 who started an SGLT2 inhibitor and 86,047 who started a DPP-4 inhibitor, all adults aged 18 to 65 with type 2 diabetes.

Over 18 months, ischemic optic neuropathy showed up in 8.5 per 10,000 GLP-1 users, compared with 5.5 per 10,000 among SGLT2 users. That works out to about 3 extra cases for every 10,000 people treated. Against DPP-4 users the gap was similar, 7.8 versus 4.2 per 10,000. Of the 81 cases among GLP-1 users, 85% were in people aged 50 or older and 70% were in men, which fits the known profile of who tends to develop this condition.

The Swedish study: the risk faded in metformin users

Peter Ueda and colleagues at the Karolinska Institute in Sweden took a different route, following 107,518 GLP-1 users and 185,898 SGLT2 users through national health registers from 2013 to 2024. They looked specifically at anterior ischemic optic neuropathy, or AION.

At one year, 0.04% of GLP-1 users had developed AION versus 0.02% of SGLT2 users, which works out to a relative risk of 1.93. In plain terms the rate was close to double, but it started from a tiny base: 62 cases among more than 107,000 people. Here is the detail that matters most. When the researchers looked only at people also taking metformin, the increased risk shrank substantially and was no longer clearly present. That pattern hints the association may be driven partly by confounding, meaning something other than the drug itself, rather than a direct effect of GLP-1 medications on the optic nerve.

What is NAION, and why might GLP-1 drugs be involved?

NAION happens when blood flow to the front of the optic nerve is suddenly reduced, damaging the nerve fibres that carry signals from the eye to the brain. The result is usually painless vision loss in one eye, often noticed on waking, and it can be permanent. It is the second most common cause of optic-nerve-related vision loss after glaucoma, and it becomes more likely with age, high blood pressure, diabetes, sleep apnea, and a particular "crowded" optic disc shape that some people are born with.

Why a GLP-1 medication might tip this balance is still being worked out. One leading idea is that rapid changes in blood sugar and blood pressure during early treatment could briefly stress the small vessels feeding the optic nerve. Another is simply that people who develop this condition already share risk factors, older age, diabetes, cardiovascular disease, with the people most likely to be prescribed these drugs. Researchers are still investigating which explanation carries more weight, and no biological mechanism has been confirmed.

How worried should you actually be?

Bottom line: this is a real but small signal, not a reason for most people to stop an effective medication. Jessica Steen, an optometrist who reviewed the findings, put the absolute risk at roughly one additional case for every 2,500 to 3,300 patients treated over 1.5 to 3 years. She concluded that the overall risk-benefit profile "remains highly favorable for most patients" and that the data do not justify extra eye screening beyond standard diabetic eye care.

The risk is not spread evenly, though. You are more likely to be affected if several of these apply to you:

• You are over 50, and especially if you are male
• You have diabetes, high blood pressure, or established cardiovascular disease
• You have obstructive sleep apnea
• You have already had NAION in one eye, which raises the risk in the other
• An eye doctor has told you that you have a small or "crowded" optic disc

If none of these fit you, the extra risk from a GLP-1 medication is extremely small. If several do, it is worth a conversation with your doctor, not an automatic reason to stop.

What you can do to protect your eyes on GLP-1 medications

You cannot change your age or your optic-disc anatomy, but you can influence the vascular health that keeps the optic nerve supplied with blood. Most of what protects your eyes here is the same as what protects your heart and small blood vessels.

Practical steps that make sense while you are on Ozempic, Wegovy, Mounjaro, or Zepbound:

• Know the warning sign. Sudden, painless loss or blurring of vision in one eye is a medical emergency. Do not wait to see if it improves, seek same-day care.
• Keep blood pressure and blood sugar steady rather than swinging. Ask your prescriber about your dose-increase schedule if your numbers are moving fast.
• Get sleep apnea treated if you have it. It is both a NAION risk factor and common in people who qualify for these drugs.
• Keep up with routine eye exams, particularly if you have diabetes.
• Protect your micronutrient status, because the appetite drop that drives weight loss also shrinks the raw material your blood vessels and nerves rely on.

That last point is easy to overlook. GLP-1 medications work by cutting how much you eat, and eating less means many users fall short on the nutrients tied to vascular and nerve health, including vitamin B12, folate, vitamin D, magnesium, and omega-3 fats. Low vitamin B12 and folate, for example, allow homocysteine to rise, and elevated homocysteine is associated with poorer small-vessel health. No supplement has been shown to prevent NAION, and it would be wrong to promise that one could. But keeping your nutrient status intact supports the same circulation your optic nerve depends on, and it guards against the fatigue, low mood, and muscle loss that nutrient gaps cause on their own.

This is the gap GLP-1 Shield is built to close. It is designed around the specific deficiencies that open up during GLP-1 therapy, so the nutrients your nerves and blood vessels need are not quietly draining away in the background while you focus on the number on the scale.

Frequently asked questions

Can Ozempic or Wegovy cause blindness?

These medications are linked to a small increase in ischemic optic neuropathy, a rare condition that can cause permanent vision loss in one eye. The risk is very low, on the order of one extra case per 2,500 to 3,300 people treated, and the two 2026 studies could not prove the drug directly causes it. For most people the benefits outweigh this risk, but any sudden vision change should be treated as an emergency.

Which GLP-1 drugs are involved, semaglutide or tirzepatide?

Most of the data so far centres on semaglutide, the ingredient in Ozempic and Wegovy, because it has been on the market longest and appeared in the original 2024 study. The 2026 studies looked at GLP-1 medications as a class. There is not yet enough separate data to say whether tirzepatide, sold as Mounjaro and Zepbound, carries a different level of risk.

Should I stop my GLP-1 medication because of the eye risk?

Not on your own. Eye specialists reviewing the 2026 data concluded that the benefits still outweigh this small risk for most patients, and that no extra screening is needed beyond standard care. If you have several NAION risk factors, such as being over 50, male, or having had it in one eye already, discuss it with your doctor rather than stopping abruptly.

What are the warning signs of NAION?

The classic sign is sudden, painless loss or dimming of vision in one eye, often first noticed on waking. Some people describe a dark area or a curtain over part of their sight, and there is usually no pain. Because early assessment matters and the damage can be permanent, any sudden vision change while on a GLP-1 medication should be checked the same day.